Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: October 29, 2003
Contact Person: Janine Guglielmino or Alexa Blasdel
P: (610) 645-4567 or (215) 431-9332 (onsite)
WHO: Living Beyond Breast Cancer
WHAT: Free teleconference, "BREAKING NEWS: Letrozole, a New Treatment Option After Tamoxifen"
WHEN: Monday, November 3, 2003, 12:00 p.m. -1:00 p.m. EST
WHY: To provide women and families affected by breast cancer and their health care providers with vital new medical information about letrozole (brand name: Femara), a treatment recently found to significantly reduce the risk of recurrence in postmenopausal women with early stage, hormone-receptor positive breast cancer.
PROGRAM: A co-author of the large, international clinical trial of letrozole will explain in understandable language the study's significance and limitations and will take questions from participants on the call. Issues to be discussed include: who benefits from letrozole; how it works; how it differs from tamoxifen; how long letrozole should be used; its possible side effects; its effectiveness versus that of other aromatase inhibitors; and whether it benefits women who completed tamoxifen therapy more than six months ago.
SPEAKERS: Edith A. Perez, MD, co-author of the study; professor of medicine, Mayo Medical School; and director, Cancer Clinical Study Unit, Mayo Clinic, Jacksonville, Florida. The program moderator is Marisa C. Weiss, MD, radiation oncologist specializing in breast cancer, Lankenau Hospital/Jefferson Health System; founder, Living Beyond Breast Cancer; founder and president, breastcancer.org.
COST: Free; pre-registration required
SPONSOR: Funded by an unrestricted educational grant from Novartis Oncology
REGISTER: Fill out an online registration form at the web site of Living Beyond Breast Cancer, or call the LBBC office at (610) 645-4567.
Living Beyond Breast Cancer, founded in 1991, is dedicated to empowering all women affected by breast cancer to live as long as possible with the best quality of life. LBBC's programs include large-scale conferences; teleconferences; the toll-free Survivors' Helpline (888-753-5222); a web site; a quarterly newsletter; Project Connect, a community outreach program; the Young Survivors Network, an educational program for women diagnosed before age 45; and workshops for health care providers.
Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

